Bo-Ragnar Tolf
Corporate Officer/Principal chez Karolinska Institutet
Profil
Bo-Ragnar Tolf is currently the Director-Innovation Office at Karolinska Institutet.
He previously worked as the Managing Director at Acadia Pharmaceuticals AB, Director at KDev Exploratory AB, Non-Executive Director at BioChromix Pharma AB, Director at Sensidose AB, and Director at Inhalation Sciences Sweden AB.
He also held the position of Vice President-Chemistry at ACADIA Pharmaceuticals, Inc. and Head-Preclinical Research at AstraZeneca AB.
He was also the Vice President-Preclinical Research & Development at Astra Arcus AB.
Dr. Tolf received his graduate and doctorate degrees from the University of Uppsala.
Postes actifs de Bo-Ragnar Tolf
| Sociétés | Poste | Début |
|---|---|---|
| Karolinska Institutet | Corporate Officer/Principal | - |
Anciens postes connus de Bo-Ragnar Tolf
| Sociétés | Poste | Fin |
|---|---|---|
| Kabi Pharmacia | Corporate Officer/Principal | 01/01/1991 |
| Pharmacia Ophthalmics AB | Directeur Technique/Scientifique/R&D | 01/01/1989 |
| SENSIDOSE AB | Directeur/Membre du Conseil | - |
KDev Exploratory AB
 KDev Exploratory AB Miscellaneous Commercial ServicesCommercial Services KDev Exploratory AB provides drug discovery solutions. It performs discovery research in various therapeutic areas, such as screening in oncology, neuroscience, lead finding, characterization in inflammation and angiogenesis/age-related macular degeneration. The company was founded by David Jern in 2000 and is headquartered in Solna, Sweden. | Directeur/Membre du Conseil | - |
| INHALATION SCIENCES SWEDEN AB | Directeur/Membre du Conseil | - |
Formation de Bo-Ragnar Tolf
| University of Uppsala | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ACADIA PHARMACEUTICALS INC. | Health Technology |
| INHALATION SCIENCES SWEDEN AB | Health Technology |
| SENSIDOSE AB | Electronic Technology |
| Entreprise privées | 7 |
|---|---|
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
| Acadia Pharmaceuticals AB | |
KDev Exploratory AB
KDev Exploratory AB Miscellaneous Commercial ServicesCommercial Services KDev Exploratory AB provides drug discovery solutions. It performs discovery research in various therapeutic areas, such as screening in oncology, neuroscience, lead finding, characterization in inflammation and angiogenesis/age-related macular degeneration. The company was founded by David Jern in 2000 and is headquartered in Solna, Sweden. | Commercial Services |
| Astra Arcus AB | |
| Pharmacia Ophthalmics AB | |
| Kabi Pharmacia | |
BioChromix Pharma AB
 BioChromix Pharma AB Miscellaneous Commercial ServicesCommercial Services BioChromix Pharma AB was founded as a subsidiary to BioChromix AB. The Company is a pharmaceutical company active in research and development of novel treatments for neurodegenerative disorders based on its proprietary technology for therapeutics. Current research and development is focused on the indication area of Alzheimer's disease but the prion diseases, Parkinson's disease and other neurodegenerative disorders might also be included in the future. BioChromix Pharma is performing pre-clinical development but is looking to reach the clinical phase within the coming years. Alzheimer's disease is the most common neurodegenerative disease, affecting around 25 million people and the costs associated with AD are tremendous. At the moment, there are no efficient treatments for AD but there are clinical trials are ongoing and some are focused at reducing the levels of the neurotoxic Aß peptide. The portfolio of the company includes a number of newly discovered lead compounds that are under investigation. | Commercial Services |